What's Happening?
Melatonin, a hormone commonly used as a sleep aid, has seen a significant increase in use among children worldwide. This trend is largely driven by its reputation as a natural and accessible solution for insomnia. However, recent research indicates that
the rapid adoption of melatonin has outpaced scientific understanding of its long-term safety and efficacy in children. While melatonin shows benefits for children with neurodevelopmental conditions, evidence for its use in typically developing children is limited. Concerns have been raised about inconsistent dosing in over-the-counter products, unsupervised use, and accidental ingestions. A review by Boston Children's Hospital highlights the need for more caution, regulation, and evidence-based guidance in using melatonin for pediatric sleep issues.
Why It's Important?
The widespread use of melatonin among children has significant implications for public health and pediatric care. As sleep difficulties become more common, parents often turn to melatonin as a quick solution, perceiving it as a safe alternative to prescription medications. However, melatonin is a hormone that affects more than just sleep, influencing immune function, metabolism, and reproductive processes. The lack of long-term safety data raises concerns about potential impacts on puberty, neurological development, and overall health. The review underscores the importance of treating melatonin as a biologically active hormone rather than a harmless supplement, advocating for stronger regulation and oversight to ensure safe use.
What's Next?
Experts recommend that melatonin should not be used as a quick fix for childhood sleep problems. Instead, behavioral sleep strategies should remain the primary treatment for insomnia in children. These include maintaining consistent bedtime routines and limiting screen exposure before bed. If melatonin is used, it should be under medical supervision, starting with the lowest effective dose and limiting the duration of treatment. The review calls for stronger oversight of melatonin products, clearer labeling standards, and more long-term clinical research to ensure safe and effective use in children.
